Consensus Documents

Consensus documents are the result of the work of expert panels from different countries or several organisations summarizing current knowledge and guidelines on a topic, and drafting operative protocols and recommendations, identifying current gaps and providing next steps. The following documents are not intended to be formal evidence-based guidelines.

All Consensus Documents
  • CONSENSUS DOCUMENT
    2025

    AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper

  • CONSENSUS DOCUMENT
    2024

    Digitally-enabled, person-centred care (PCC) in allergen immunotherapy: An ARIA-EAACI Position Paper

  • CONSENSUS DOCUMENT
    2024

    Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force

  • CONSENSUS DOCUMENT
    2024

    EAACI/ENDA position paper on drug provocation testing

  • CONSENSUS DOCUMENT
    2023

    Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

  • CONSENSUS DOCUMENT
    2023

    Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach – ARIA-EAACI Task Force Report

  • CONSENSUS DOCUMENT
    2023

    The One Health approach for allergic diseases and asthma

  • CONSENSUS DOCUMENT
    2022

    Allergies and COVID-19 vaccines: An ENDA/ EAACI Position paper

  • CONSENSUS DOCUMENT
    2022

    Cannabis-related allergies: an international overview and consensus recommendations

  • CONSENSUS DOCUMENT
    2022

    Molecular Allergology User’s Guide 2.0

  • CONSENSUS DOCUMENT
    2021

    ERS/EAACI statement on adherence to international adult asthma guidelines

  • CONSENSUS DOCUMENT
    2021

    Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus

  • CONSENSUS DOCUMENT
    2021

    ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – an EAACI-ARIA position paper

  • CONSENSUS DOCUMENT
    2021

    ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)

  • CONSENSUS DOCUMENT
    2021

    COVID-19 pandemic: Practical considerations on the organization of an allergy clinic – An EAACI/ARIA position paper

  • CONSENSUS DOCUMENT
    2020

    Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statemen

  • CONSENSUS DOCUMENT
    2020

    Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

  • CONSENSUS DOCUMENT
    2019

    Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document

  • CONSENSUS DOCUMENT
    2018

    EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents